Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults in Africa.
Brief Summary: CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the London School of Hygiene and Tropical Medicine, University of Liverpool and the Liverpool School of Tropical Medicine as a treatment for acute uncomplicated P. falciparum malaria.

The combination of chlorproguanil HCl (CPG) and dapsone (DDS) as chlorproguanil-dapsone has already been shown to be efficacious against P.falciparum in adults and children in Sub-Sahara Africa. The addition of artesunate to LAPDAP has been demonstrated to increase the parasite kill rate as demonstrated in the phase II study, and reduce the chance of any parasites escaping treatment over the 3-day course. The addition of artesunate is also anticipated to have the population benefit of protection against the development of resistant strains of P.falciparum, although it will not be possible to demonstrate this in a clinical trial. One further population benefit of the artemisinin drugs are their ability to suppress the sexual forms of the parasite (gametocytes), which should reduce infectivity after antimalarial treatment and potentially lower transmission rates with widespread use, including the spread of any parasites resistant to the partner drug.

The aims of this phase III study are to compare the efficacy of a fixed ratio combination tablet of CDA to chlorproguanil-dapsone, and collect supporting safety data. This will be a multi-centre, double-blind, double-dummy, randomised trial, in children, adolescents and adults, with chlorproguanil-dapsone as a comparator.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
C: Arm Label: Eurartesim (control); Type: OTHER; Interventions: Drug: DHA-PPQ | Arm Label: Primaquine 0.75mg base/kg; Type: EXPERIMENTAL; Interventions: Drug: DHA-PPQ, Drug: PQ (0.75) | Arm Label: Primaquine 0.4mg base /kg; Type: EXPERIMENTAL; Interventions: Drug: DHA-PPQ, Drug: PQ (0.4) | Arm Label: Primaquine 0.2mg base/kg; Type: EXPERIMENTAL; Interventions: Drug: DHA-PPQ, Drug: PQ (0.2) | Intervention Type: DRUG; Name: DHA-PPQ; Assigned to Arm(s): Eurartesim (control), Primaquine 0.2mg base/kg, Primaquine 0.4mg base /kg, Primaquine 0.75mg base/kg | Intervention Type: DRUG; Name: PQ (0.75); Assigned to Arm(s): Primaquine 0.75mg base/kg | Intervention Type: DRUG; Name: PQ (0.4); Assigned to Arm(s): Primaquine 0.4mg base /kg | Intervention Type: DRUG; Name: PQ (0.2); Assigned to Arm(s): Primaquine 0.2mg base/kg
D: Arm Label: Artemether-Lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Arm Label: Artemether-Lumefantrine-Primaquine 0.25; Type: EXPERIMENTAL; Interventions: Drug: Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine | Arm Label: Artemether-Lumefantrine-Primaquine 0.4; Type: EXPERIMENTAL; Interventions: Drug: Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-Lumefantrine | Intervention Type: DRUG; Name: Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine; Assigned to Arm(s): Artemether-Lumefantrine-Primaquine 0.25 | Intervention Type: DRUG; Name: Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine; Assigned to Arm(s): Artemether-Lumefantrine-Primaquine 0.4

Answer: B